Fine Foods & Pharmaceuticals N.T.M. SpA (FF) AI Stock Analysis

• Market Cap: €180.39M
• Dividend Yield: 1.63%
• Average Volume (3M): 10.94K
• Price to Earnings (P/E): 19.3
• Beta (1Y): 0.15
• Revenue Growth: -4.22%
• EPS Growth: N/A
• Country: IT
• Employees: 779
• Sector: Consumer Defensive
• Sector Strength: 68
• Industry: Packaged Foods
• EPS (TTM): 0.17
• Shares Outstanding: 22,060,125
• 10 Day Avg. Volume: 5,058
• 30 Day Avg. Volume: 10,943
• PEG Ratio: 0.18
• Price to Book (P/B): 1.39
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 16.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €11.70
• Price Target Upside: 58.54% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 64 Neutral
• Price Target: €8.00 ▲(8.40%Upside)

The company's overall stock score is driven primarily by its moderate financial health and positive technical indicators, despite valuation concerns. The financial performance, characterized by a strong equity position and improving cash flow, is the most significant factor. Technical analysis indicates a positive trend, though the valuation suggests potential overvaluation.

Positive Factors

Earnings

1Q25 was the best ever in terms of EBITDA and margin, achieved fully organically and through traditional actions.

Financial Performance

Record profitability was boosted by the Cosmetics repositioning, contributing to improved margins and profitability.

Negative Factors

Growth

The Nutra business unit is expected to have slower growth assumptions, leading to a slight reduction in group revenue.

Revenue

A relatively challenging YoY comparison and different order phasing led to a drop in group revenues.

Fine Foods & Pharmaceuticals N.T.M. SpA Business Overview & Revenue Model

Company Description

Fine Foods & Pharmaceuticals N.T.M. SpA (FF) is a leading Italian contract development and manufacturing organization (CDMO) specializing in the production of pharmaceuticals, nutraceuticals, and cosmetics. The company operates within the health and wellness sectors, offering a comprehensive range of services from product development to manufacturing and packaging. FF is known for its commitment to quality and innovation, serving a diverse clientele that includes major pharmaceutical and consumer health companies.

How the Company Makes Money

Fine Foods & Pharmaceuticals N.T.M. SpA generates revenue primarily through its contract development and manufacturing services. The company's key revenue streams include the production and supply of pharmaceuticals, nutraceuticals, and cosmetics for third-party brands. FF partners with pharmaceutical and consumer health companies to develop and manufacture products under their brand names, providing end-to-end solutions that include formulation, production, and packaging. The company benefits from long-term contracts and significant repeat business from its clients, leveraging its expertise and state-of-the-art facilities to meet stringent quality standards and regulatory requirements. Strategic partnerships and a strong focus on innovation further bolster FF's earnings, enabling it to maintain a competitive edge in the CDMO market.

Fine Foods & Pharmaceuticals N.T.M. SpA Financial Statement Overview

Summary

Fine Foods & Pharmaceuticals N.T.M. SpA exhibits moderate financial health with stable profitability in a competitive industry. While revenue growth has faced challenges, the company maintains a solid equity position and effective cash flow management. Future focus should be on enhancing operational efficiency and driving consistent revenue growth.

Income Statement

The company shows moderate profitability with a gross profit margin of approximately 41.8% and a net profit margin of 3.3% as of 2024. Revenue growth has been inconsistent, with a decline in 2024 compared to 2023. EBIT and EBITDA margins remain relatively low, indicating room for improvement in operational efficiency.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.41, indicating reliance on equity over debt. The equity ratio is strong at 54.4%, reflecting a solid equity base. However, the return on equity is low at 6.2%, suggesting limited profitability relative to shareholder investment.

Cash Flow

Cash flow performance is improving, with free cash flow turning positive in 2024. The operating cash flow to net income ratio is robust at 5.62, reflecting strong cash generation relative to earnings. The free cash flow to net income ratio is 1.36, indicating effective cash management.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
243.75M	251.81M	206.85M	194.42M	173.03M
	Gross Profit
101.83M	67.74M	53.63M	54.90M	49.23M
	EBIT
14.64M	1.07M	-1.75M	7.52M	10.79M
	EBITDA
30.90M	19.29M	3.64M	9.86M	29.18M
	Net Income Common Stockholders
8.16M	-3.52M	-9.50M	-1.43M	13.36M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
19.21M	19.15M	76.74M	95.09M	74.95M
	Total Assets
242.59M	241.56M	299.82M	302.81M	207.44M
	Total Debt
54.53M	66.39M	120.36M	110.76M	21.19M
	Net Debt
35.32M	47.39M	110.13M	93.65M	17.85M
	Total Liabilities
110.53M	114.61M	166.53M	155.59M	66.43M
	Stockholders Equity
132.06M	126.95M	133.29M	147.22M	141.01M
Cash Flow		Free Cash Flow
11.12M	-329.75K	-12.30M	-21.75M	14.66M
	Operating Cash Flow
45.85M	18.54M	3.69M	-5.83M	30.47M
	Investing Cash Flow
-31.56M	45.89M	-15.31M	-36.35M	-12.34M
	Financing Cash Flow
-14.08M	-55.66M	4.74M	55.95M	-17.41M

Fine Foods & Pharmaceuticals N.T.M. SpA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.38
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:FF, the sentiment is Positive. The current price of 7.38 is below the 20-day moving average (MA) of 7.42, above the 50-day MA of 7.17, and below the 200-day MA of 7.49, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 52.81 is Neutral, neither overbought nor oversold. The STOCH value of 61.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:FF.

Fine Foods & Pharmaceuticals N.T.M. SpA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
REY	74 Outperform	€5.61B	26.63	17.49%	0.76%	8.40%	13.09%
CIR	71 Outperform	€552.38M	4.77	-1.45%	―	-23.48%	―
Sector *	65 Neutral	$8.88B	14.98	4.76%	203.76%	3.54%	-2.49%
FF	64 Neutral	€180.39M	19.27		1.63%	-4.22%	―